

Oncobiologics, Inc.
Form 8-K
February 07, 2018

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 1, 2018**

Oncobiologics, Inc.

(Exact name of registrant as specified in its charter)

Delaware **001-37759** **38-3982704**
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

7 Clarke Drive
Cranbury, New Jersey
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(609) 619-3990**

(Former name or former address, if changed since last report)

Edgar Filing: Oncobiologics, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 1.01. Entry into a Material Definitive Agreement.

On February 1, 2018, Oncobiologics, Inc. (the “Company”) entered into the sixth amendment to the lease for its corporate headquarters located at 7 Clarke Drive, Cranbury, NJ. Under the sixth amendment, the Company leased approximately 21,274 square feet of adjacent laboratory and office space commencing March 1, 2018 for a term of 10 years. The term of the existing lease has also been extended until February 28, 2028. Under the amendment, the Company will make additional monthly lease payments of \$42,548 from March 1, 2018 through February 28, 2023, increasing to \$48,930 beginning March 1, 2023 through the end of the lease.

The foregoing description of the lease amendment is qualified in its entirety by reference to the sixth amendment to the lease agreement, which is filed as Exhibit 10.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
<u>10.1</u>	<u>Sixth Amendment to Lease Agreement by and between Oncobiologics, Inc. and Cedar Brook 7 Corporate Center, LP, dated as of February 1, 2018.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oncobiologics, Inc.

Date: February 7, 2018 By: /s/ Lawrence A. Kenyon
Lawrence A. Kenyon
Chief Financial Officer